Skip to main content
. 2022 Aug 25;14(9):1771. doi: 10.3390/pharmaceutics14091771

Figure 10.

Figure 10

CLSM images of RLX/NRG permeation across the intestinal mucosal membrane treated with (A) rhodamine B-labeled RLX/NRG NLCs and (B) the rhodamine B-labeled RLX/NRG suspension.